What is the DELFI Study?
Cleveland Clinic is participating in the DELFI Study, an observational study that aims to determine if a blood test, being developed by Delfi Diagnostics (also the study sponsor), can detect lung cancer. Additionally, the study aims to see if a blood test can identify other types of cancers and health conditions.
How does the DELFI study work?
The DELFI study plans to enroll approximately 1700 people across several health systems, and participation includes a blood draw and medical record review a year later.
Why should I participate?
Despite many advances, lung cancer remains the leading cause of cancer-related death worldwide. The earlier cancer is diagnosed, the better the chance of successful treatment. Most lung cancers are still not detected until too late when outcomes are poor. The current lung cancer screening guidelines recommend a baseline chest low dose computed tomography (LDCT) scan in a select group of at-risk individuals to identify lung cancer at an early stage. Participating in this study may help in the further development of a blood test to provide more information for people who are at an increased risk of developing lung cancer.
Your participation could make a difference for your family and your community, as well improve treatment outcomes for cancer patients around the world.
Who is eligible to participate?
The study is currently open to men and women aged 50 years or older who are either:
Individuals with an increased risk of cancer, meaning they are:
Individuals who currently or previously smoked with a smoking history of at least 20 pack years (eg. smoked 1 pack per day for 20 years)
AND are 1 of the following
Individuals who have had a CT scan within a year or are scheduled for a CT scan in the next 6 weeks
Individuals who have recently been diagnosed with lung cancer or a cancer other than lung cancer and have not started treatment
How do I sign up?
If you are interested in finding out if you are a candidate for the study, please complete this form. A study coordinator will be in contact to discuss your eligibility and next steps.
If eligible, the initial consultation will be conducted virtually, and an appointment for collection of a blood sample will be scheduled at one of the Cleveland Clinic locations below. You must have a scheduled appointment for collection of a blood sample.
Once you are contacted by the coordinator and are eligible for the study, you will be provided a consent form via email or by regular mail. We thank you for your interest in the DELFI study.